|
MTTI is a privately held Biotechnology Company located in West Chester, PA. The company’s focus is on early-stage innovative technology development and works closely with Universities and Government Agencies. Current areas of development include:
- Medical imaging agents for diagnosis of cardiovascular disease and cancer
- 99mTc-glucarate for cardiac imaging
- Radiohybridization PET probe [64Cu-DO3A-CCND1 PNA-D(CSKC)] for breast cancer imaging
- Nanovesicles (SapC-DOPS) for tumor imaging
- Recombinant oral rabies vaccine for wildlife
- Anthrax and Botulinum toxin vaccines employing fusion protein technology
- Cell-Permeable Caveolin-Mimetic Peptides for potential treatment of pulmonary hypertension and cardiac ischemic injury
MTTI has also licensed worldwide rights to manufacture, sell and/or distribute innovative proprietary fluorescence based technologies and novel bead based technologies from PTI Research Inc. (PTIR).These products include NeuroVue® , CellVue® and Immobilized Steroid Bead product lines for in vitro and in vivo research applications. Additionally, MTTI provides custom synthetic and analytical chemistry services.
MTTI is seeking corporate partners for further development of their products and technologies.
|
Molecular Targeting Technologies Inc.